Navigation Links
Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
Date:11/9/2007

peptide therapeutics. The Company's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. The Company currently has collaborations with AstraZeneca and the Mallinckrodt division of Covidien. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Forward-looking Statements

Statements about the Company's future expectations, including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements shall be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to the Company's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R), ability to protect its intellectual property, and other factors discussed in the Company's periodic filings with the Securities and Exchange Commission. The Company is not responsible for u
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
7. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
10. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
11. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 The Dohmen Company today ... Ph.D., MBA as Chief Science Officer (CSO) of ... created role, Dr. Floyd will lead Dohmen,s growing ... of pre-commercial and post approval outsourced services in ... communications.  Dr. Floyd brings decades of experience leading ...
(Date:9/1/2015)... ... 01, 2015 , ... Industry leader iLab Solutions recently announced ... newly-created position, Gibbs will lead iLab’s business operations in the region, with an ... entails not only introducing iLab to potential partners but support and management of ...
(Date:9/1/2015)... 1, 2015 Shire plc (LSE: SHP, ... Mathew to its Board of Directors as a Non-Executive ... Compliance & Risk Committee of the Shire Board. Both appointments ... Sara previously served as Chairman, President and Chief Executive Officer ... During her 12-year tenure at D&B, she helped drive the ...
(Date:8/31/2015)... -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) aclinical stage ... antibody, HuMab 5B1, will be garnering major attention as ... World Molecular Imaging Congress (WMIC) being held in ... the Department of Radiology at Memorial Sloan Kettering Cancer ... MabVax,s lead antibody as a PET imaging agent and ...
Breaking Biology Technology:Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4
... Inc.,(Nasdaq: RDEA ) announced today that Barry D. Quart, PharmD, ... UBS Global Life Sciences Conference, Date: ... Time Location: Grand Hyatt, New York ... Focus Conference, Date: Tuesday, October 7, 2008 ...
... Serve Growing Highly-Potent and Cytotoxic ... ... Pharmatek -- a,pharmaceutical chemistry development organization supporting the,pharmaceutical industry -- ... in San Diego., The 18,000 sq. ft. facility includes ...
... the use of sensors or barcodes at the nanoscale, North ... tiny organic particles, when heated to the proper temperature, bob ... film and then can reversibly recede below the surface when ... of particles to a surface and then sinking them back ...
Cached Biology Technology:Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference 2Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility 2NC State engineers discover nanoparticles can break on through 2
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/31/2015)... 31, 2015 Growing need for ... government digitization projects to drive India ... TechSci Research report, " India Biometrics Market Forecast & Opportunities, ... is projected to grow at a CAGR of over 35% ... on account of extensive use of biometric technology in the ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has announced the ... - Growth, Trends & Forecasts (2014-2020)" report to ... Sensors market is estimated at $0.23 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2
... 03, 2010, Seoul, S. Korea Institut Pasteur Korea ... the chemical compound collection of Novartis Institute for Tropical ... IP-K,s PhenomicScreen is a high-throughput, high-content visual screening ... Over the past year, PhenomicScreen has been used to ...
... Intense, individually tailored dietary treatment for acutely hospitalized elderly ... new study by researchers at Ben-Gurion University of the ... prestigious Journal of the American Geriatric Society ... percent) of the control group compared to the intervention ...
... Several of the most promising technological research projects at ... infusion of federal cash to help them through the ... the commercial market. With $5.1 million in federal ... System of Maryland research institutions and the U.S. Army ...
Cached Biology News:Personalized diets for elderly after hospitalization decreases mortality rates 2$5.1 million Army-Md. alliance speeds university research to market 2$5.1 million Army-Md. alliance speeds university research to market 3$5.1 million Army-Md. alliance speeds university research to market 4$5.1 million Army-Md. alliance speeds university research to market 5
Non-Receptor Tyrosine Kinase Sampler Kit 10 mu g each...
Mouse monoclonal [N7519] to NR0B2 ( Abpromise for all tested applications). Antigen: E.coli expressed recombinant full length protein (Human) NR0B2 Entrez Gene ID: 8431 Swiss Protein ID: ...
DNA Repair Sampler Kit 10g each...
Zonula Adherens Sampler Kit 10 mu g each...
Biology Products: